Understanding the physiology of extreme altitude transforms every decision you make on a high-altitude objective — from acclimatisation schedule design to supplemental oxygen flow rate selection to the interpretation of a partner’s unusual behaviour. The science is not abstract: it directly explains why cognitive impairment at 8,000m makes turnaround decisions unreliable, why supplemental oxygen flow rates need to change between sleep and summit push, and why HACE and HAPE can each kill a climber who looked fine six hours earlier.
Why understanding physiology makes you a better decision-maker
Most mountaineering safety guidance tells you what to do — descend if you can’t walk a straight line, use 2 L/min on summit day — without explaining the mechanism. Understanding the mechanism allows you to generalise the principle to situations the rules don’t explicitly cover, to recognise early physiological warning signs before they become clinical emergencies, and to understand why the rules are structured the way they are rather than memorising them as arbitrary protocols.
At extreme altitude, the margin between “managing adequately” and “declining rapidly” is narrow, the warning signs are often masked by the environment and by the impaired cognition of the affected person, and the decision timelines are compressed by distance from rescue. A climber who understands the physiology makes better decisions earlier in the deterioration curve.
Altitude zones and their physiological profiles
3,000–5,000m
Acclimatisation zone
~60–70% O₂ availability
This is the altitude range where meaningful acclimatisation occurs and is sustainable. The body responds to reduced oxygen with increased ventilation, increased red blood cell production (erythropoiesis), and cardiovascular adaptations that progressively restore oxygen delivery capacity toward baseline. AMS symptoms are common at initial exposure but typically resolve within 24–48 hours at stable elevation. Sleep at this altitude is disrupted but not deeply compromised. The acclimatisation zone is where expedition teams spend their rotation time — gaining altitude during the day for physiological stimulus, returning to this zone to sleep for effective adaptation.
5,000–7,000m
Extreme altitude
~50–60% O₂ availability
Performance degrades significantly but recovery is still possible with adequate time at altitude. Full acclimatisation is not achievable in this zone — the body cannot fully compensate for oxygen availability this low — but meaningful adaptation continues. Aerobic capacity at 6,000m is approximately 50–60% of sea-level maximum for the same individual. Sleep quality deteriorates substantially — Cheyne-Stokes breathing becomes common and periodic arousals reduce deep sleep to near-zero above 6,500m in many climbers. Extended residence (weeks to months) causes gradual physiological deterioration despite acclimatisation. Most Himalayan high camps are in this zone.
7,000–8,000m
High altitude
~37–45% O₂ availability
Prolonged exposure causes physiological damage that does not reverse while at altitude. Above 7,000m, the body’s compensatory mechanisms are fully engaged but insufficient — the cardiovascular and respiratory systems are operating at or near their limits continuously. Tissue damage begins accumulating with each hour of exposure. Cognitive function measurably degrades — executive function, decision-making quality, and risk assessment are all impaired in ways the affected person cannot self-detect reliably. Most experienced high-altitude climbers consider this the lower boundary of the death zone for practical management purposes, even though 8,000m is the conventional threshold.
8,000m+
Death zone
~33–36% O₂ availability
The body cannot acclimatise to the death zone — it can only deteriorate more or less rapidly. Above 8,000m, all physiological processes are under sustained stress that cannot be fully compensated. Tissue damage accumulates continuously, cognitive impairment is significant, sleep at the summit push camps is near-impossible without supplemental oxygen, and the cardiovascular system is at its operational ceiling. The strategic question at 8,000m is not “how do we maintain performance here” but “how quickly can we achieve our objective and descend before the deterioration becomes irreversible.” Speed and timing are the primary management tools; skill matters less than at lower altitudes because physiological limits dominate performance.
Key physiological processes at extreme altitude
Hypoxia and the oxygen cascade
The oxygen cascade is the pathway oxygen takes from ambient air to mitochondria — from atmosphere (where partial pressure decreases with altitude) through the lungs, into the blood, to the tissues. At each step in the cascade, altitude reduces the available driving pressure. At sea level, the alveolar partial pressure of oxygen (pO₂) is approximately 100 mmHg. At Everest summit, it’s approximately 35 mmHg — a reduction of 65%.
The body compensates at each cascade step: increased breathing rate (moves more air through the lungs), increased cardiac output (pumps blood faster), and increased haemoglobin concentration (carries more oxygen per unit blood). These compensations are effective up to approximately 7,000m, where they approach their biological limits.
Clinical implication: SpO₂ (peripheral oxygen saturation) is the practical field measurement of how well the oxygen cascade is functioning. A resting SpO₂ below 70% at altitude correlates strongly with severe altitude illness risk. Track trends — a 5% decline over 24 hours is more concerning than a stable reading at any level.
Erythropoiesis: red blood cell production
Hypoxia stimulates the kidneys to produce erythropoietin (EPO), which signals bone marrow to accelerate red blood cell (RBC) production. Over 10–21 days of altitude exposure, haemoglobin concentration increases by 10–20%, and total red blood cell mass increases substantially. This is the primary long-term acclimatisation mechanism — the same adaptation exploited by altitude training camps and altitude tents.
Erythropoiesis has a time cost: it takes 7–14 days to produce meaningful RBC increases at altitude. This is why acclimatisation schedules that spend less than a week at each elevation increment are physiologically inadequate — the body hasn’t had time to produce the RBCs that make each elevation sustainable.
Clinical implication: Haematocrit (the fraction of blood that is red blood cells) can increase to dangerous levels with prolonged altitude exposure — above ~55–60%, blood viscosity increases stroke and clotting risk. Adequate hydration at altitude is partly a haematocrit management strategy, not just comfort.
Sleep-disordered breathing: Cheyne-Stokes respiration
Cheyne-Stokes respiration (CSR) is an abnormal breathing pattern characterised by cycles of gradually increasing breathing rate and depth, followed by a brief period of apnoea (no breathing), followed by another increasing cycle. At altitude, CSR is triggered by the respiratory control system’s instability in the hypoxic environment — the chemoreceptors that regulate breathing overshoot and undershoot their targets repeatedly through the night.
CSR produces frequent arousal from sleep — the brief periods of apnoea cause sufficient oxygen desaturation to trigger arousal, often without the climber being aware of it. The result is severely fragmented sleep architecture, with deep sleep (slow-wave and REM) dramatically reduced or absent above approximately 6,000m without supplemental oxygen.
Clinical implication: Acetazolamide (Diamox) at prophylactic doses reduces CSR severity by stimulating baseline ventilation, improving sleep quality at altitude. Supplemental oxygen at 0.5 L/min during sleep virtually eliminates CSR above 8,000m by maintaining sufficient pO₂ to stabilise the respiratory control system.
Cognitive impairment: judgment degradation above 7,000m
Cognitive impairment at altitude is one of the most comprehensively documented and practically dangerous altitude effects. The brain is exquisitely sensitive to oxygen deficiency — cognitive processing speed, working memory, executive function, and risk assessment all degrade measurably above approximately 5,000m, and the degradation accelerates steeply above 7,000m.
The most dangerous aspect of altitude-induced cognitive impairment is that it impairs the capacity to recognise itself. The affected climber typically feels that they are functioning normally while exhibiting measurably reduced performance on standardised cognitive tests. This is why pre-committed decision frameworks, written turnaround criteria, and team cross-monitoring are essential at extreme altitude — the climber cannot reliably assess their own cognitive status.
Clinical implication: Decision-making quality at 8,000m without supplemental oxygen is roughly equivalent to a blood alcohol level of 0.05–0.08% in several studies. At this level, the affected person feels unimpaired while displaying measurable judgment degradation. Any decision made above 7,500m without supplemental oxygen should be treated as potentially impaired.
Cognitive impairment by altitude
How judgment degrades with elevation — the clinical picture
5,000–6,500m
Mild slowing of processing speed and reaction time. Memory consolidation slightly impaired. Most climbers not consciously aware of impairment. Complex problem-solving takes measurably longer.
Decision quality: Adequate for most decisions. Pre-committed frameworks still improve outcomes. Begin using written protocols rather than relying on memory.
6,500–7,500m
Working memory capacity significantly reduced. Risk assessment systematically biased toward optimism (summit fever amplified by physiology). Judgment about turnaround criteria reliably degraded in experimental settings. Emotional regulation impaired — frustration, fixation, and irrational decision persistence all increase.
Decision quality: Pre-committed written criteria essential. Team cross-monitoring required. Self-assessed “I feel fine” is unreliable at this elevation. Trust the protocol over the feeling.
7,500m+ (without supplemental O₂)
Executive function severely degraded. Documented cases of experienced climbers unable to perform simple arithmetic or recall the sequence of safety protocols they wrote themselves. Spatial orientation may be impaired. At 8,000m+ without O₂, cognitive function is comparable to significant intoxication in measurable tests.
Decision quality: The most experienced climber on the team at this altitude is still cognitively impaired. Pre-committed turnaround times must be honoured regardless of how the decision “feels” in the moment. Supplemental O₂ at 1–2 L/min meaningfully improves decision-making quality at these elevations.
HACE and HAPE: mechanisms, early warning signs, and field treatment
High Altitude Cerebral Edema (HACE) and High Altitude Pulmonary Edema (HAPE) are the two life-threatening altitude illnesses — distinct from AMS (acute mountain sickness) in mechanism, presentation, and severity. Both can be fatal within hours if descent is delayed. At expert altitude, both are more common, more rapidly progressive, and harder to treat than at intermediate altitude because the distances and conditions make rapid descent more difficult.
Mechanism
Hypoxia causes breakdown of the blood-brain barrier, allowing fluid to leak into brain tissue. The resulting cerebral oedema (swelling) increases intracranial pressure, compressing brain structures and progressively impairing function.
Early warning signs (act before these progress)
Severe headache unrelieved by ibuprofen or paracetamol
Confusion or unusual behaviour — saying things that don’t make sense
Ataxia — positive heel-to-toe walk test is a clinical HACE indicator
Drowsiness — difficulty staying awake is a late and dangerous sign
Field treatment protocol
Immediate descent — at least 500–1,000m or until symptoms begin to resolve. Dexamethasone 8mg initial dose (IM or oral) reduces cerebral oedema during descent — this buys time but does not replace descent. Supplemental oxygen if available. Do not wait for morning. Do not wait for weather to improve if descent is feasible. HACE has a mortality rate that increases sharply with each hour of delayed descent.
Mechanism
Hypoxia causes pulmonary vasoconstriction (narrowing of lung blood vessels), increasing pulmonary artery pressure. This forces fluid through the capillary walls into the alveoli (air sacs), impairing gas exchange and progressively reducing oxygenation — creating a vicious cycle where lower oxygenation worsens HAPE.
Early warning signs (act before these progress)
Dry cough at rest that progresses to wet, bubbly cough
Reduced exercise tolerance beyond expected altitude impairment
Breathlessness at rest — not just during exertion
Pink or frothy sputum — definitive HAPE indicator
Crackling sound in lungs (audible by placing ear to chest)
Field treatment protocol
Immediate descent — 500–1,000m minimum. Nifedipine 30mg slow-release reduces pulmonary artery pressure during descent (buy time, not replace descent). Supplemental oxygen increases SpO₂ and reduces HAPE progression during descent. HAPE is the most common cause of altitude-related death. It can progress from “reduced exercise tolerance” to “cannot be left alone” in 4–6 hours. The 2am descent in a storm is the correct decision when HAPE is suspected.
HAPE is most common on the second night at a new altitude — not the first
The physiological timeline of HAPE is counterintuitive: it most commonly develops on the second night at a new high camp, not immediately upon arrival. A climber who feels adequately acclimatised after one night at a new altitude should not interpret this as clearance — the HAPE risk window peaks around 24–48 hours after arrival. This is why daily SpO₂ monitoring with trend tracking is more valuable than single-point assessment, and why the day-two health check is as important as the arrival-day check.
Supplemental oxygen: flow rates, systems, and when to use each rate
Supplemental oxygen is the most powerful physiological intervention available to high-altitude climbers — at 2 L/min, it effectively reduces the physiological altitude by approximately 1,200–1,500m. At 8,849m on Everest, 2 L/min of supplemental oxygen produces a physiological environment comparable to approximately 7,300–7,600m — still extreme, but meaningfully more manageable. Understanding the flow rate system allows informed decisions about bottle consumption, timing, and emergency protocol.
| Situation | Flow rate | Physiological equivalent altitude reduction | Notes on bottle consumption |
|---|
| Sleeping at high camp (Camp 4, 7,950m) |
0.5 L/min |
~500–700m altitude reduction · Virtually eliminates Cheyne-Stokes · Dramatically improves sleep quality |
One 4L bottle at 200 bar lasts approximately 13 hours at 0.5 L/min. Dedicated sleeping bottles are separate from summit push allocation. Most teams designate 1 bottle per person for sleeping at Camp 4. |
| Moving at moderate pace — approach sections, lower angle terrain |
1–2 L/min |
~700–1,400m altitude reduction · Cognitive function meaningfully improved · Allows sustained movement without rest-step at every step |
1 L/min: ~13 hours per bottle. 2 L/min: ~6.5 hours per bottle. Standard allocation for ascent on non-summit sections of the route. |
| Summit push — steep terrain, high exertion |
2–3 L/min |
~1,400–2,000m altitude reduction at 3 L/min · Allows sustained climbing output on steep terrain above 8,000m |
3 L/min: ~4.5 hours per bottle. A typical Everest summit push (C4 to summit and return) takes 12–16 hours. Budget 3–4 bottles per person at mixed 2–3 L/min rates plus emergency margin. |
| Emergency — HACE/HAPE treatment or rescuer during emergency descent |
4 L/min |
~2,500m+ altitude reduction · Maximum physiological intervention available in field |
4 L/min: ~3.25 hours per bottle. Reserve a dedicated emergency bottle per team for this purpose — never use the emergency allocation for the summit push even if it appears unnecessary. |
| Regulator failure during summit push |
0 L/min |
Full altitude exposure at current elevation · Cognitive impairment onset within minutes above 8,000m |
Pre-commit to turnaround altitude if O₂ system fails. Above 8,500m without O₂, descent must begin immediately — the affected climber has insufficient cognitive capacity to assess the situation reliably. Every team member carries a backup russik and a spare regulator seal. |
Medications at extreme altitude: mechanisms and appropriate use
Mechanism
Inhibits carbonic anhydrase in red blood cells, increasing CO₂ hydration and causing metabolic acidosis. This acidifies the blood, stimulating the respiratory centre to breathe more deeply and frequently — accelerating the ventilatory acclimatisation response.
Appropriate use
Prophylactic: 125–250mg twice daily, starting 24–48 hours before ascent. Reduces AMS incidence and severity, improves sleep quality (reduces Cheyne-Stokes severity), and accelerates physiological acclimatisation. For rapid ascent schedules (Aconcagua, Kilimanjaro) where acclimatisation time is compressed.
Side effects to know
Increased urination (significant — maintain high fluid intake), tingling in fingers and face (very common, harmless), altered taste of carbonated drinks. Do a test dose 1–2 weeks before the expedition to confirm tolerance.
Contraindicated with sulfa drug allergy. Consult physician before use.
Mechanism
Potent corticosteroid that reduces cerebral oedema by decreasing blood-brain barrier permeability and reducing the inflammatory cascade. At altitude, it rapidly reduces intracranial pressure in HACE, producing symptomatic improvement within 30–60 minutes of an adequate dose.
Appropriate use
Emergency treatment of HACE: 8mg initial dose (oral or IM), then 4mg every 6 hours during descent. Also used to treat severe AMS where descent is temporarily impossible. Not for prophylaxis (suppresses the body’s natural acclimatisation response). Some climbers use 2mg before summit push — the ethics and physiology of this are debated.
Critical limitation
Dexamethasone treats HACE symptoms and buys descent time — it is not a treatment. A climber who improves on dexamethasone and remains at altitude will deteriorate again as the drug effect wears off. Descent is mandatory even when dexamethasone produces rapid symptomatic improvement.
For emergency use only — not prophylaxis. Carry and know the protocol; use only when HACE is clinically suspected.
Mechanism
Calcium channel blocker that causes pulmonary vasodilation — it relaxes the smooth muscle in pulmonary arterioles, reducing pulmonary artery pressure. This directly addresses the mechanism of HAPE (hypoxic pulmonary vasoconstriction elevating pressure to the point of fluid leakage into alveoli).
Appropriate use
Emergency treatment of HAPE: 30mg slow-release (Adalat Retard or equivalent) as initial dose during descent. Produces meaningful reduction in pulmonary artery pressure within 15–30 minutes. Unlike dexamethasone for HACE, nifedipine directly addresses the HAPE mechanism rather than just reducing symptoms.
Important caveat
Nifedipine causes systemic vasodilation — blood pressure drops significantly. In cold temperatures at extreme altitude, this can compound hypothermia risk. The drug should be used during active descent, not as a substitute for beginning descent.
HAPE emergency only. Can cause significant hypotension — monitor closely. Carry in all teams going above 5,000m.
Nutrition and hydration at extreme altitude
The altitude environment suppresses both appetite and thirst through specific physiological mechanisms — making adequate nutrition and hydration active disciplined efforts rather than natural responses to hunger and thirst signals.
Appetite suppression at altitude results from elevated leptin levels (the satiety hormone), nausea from AMS, and the metabolic acidosis produced by high ventilation rates. Caloric demand at altitude is simultaneously elevated (higher ventilation rate, higher metabolic cost of movement in cold) and harder to meet. The practical protocol is eating by schedule, not by hunger — consuming 200–400 calories per hour during active climbing regardless of appetite, and maintaining high-calorie density in all food items to maximise intake from limited volume.
Dehydration at altitude is multifactorial: increased respiratory water loss (high ventilation rate at cold, dry altitude exhales large volumes of water vapour), increased renal water loss (from acetazolamide use and altitude-induced diuresis), and suppressed thirst sensation. A climber at 7,000m in cold conditions who is not actively drinking is almost certainly dehydrating. The haematocrit management rationale reinforces aggressive hydration — dehydration concentrates the already-elevated RBC count, increasing blood viscosity and thrombosis risk. Target urine colour as a hydration indicator: pale straw is adequate; dark is dehydration.
The case for and against supplemental O₂ on 8,000m peaks
The supplemental oxygen decision on 8,000m peaks involves safety, ethics, cost, and physiology — and reasonable expert mountaineers disagree on the right framework for making it. The positions below represent honest presentations of both sides, not advocacy for either.
Dramatically reduces the probability of HACE and HAPE, which are the primary fatal altitude illnesses — a measurable safety benefit on the most dangerous section of any 8,000m peak
Meaningfully improves cognitive function in the death zone, leading to better turnaround decisions and more reliable assessment of partner condition
Makes summit-level mountaineering accessible to climbers who could not safely function at 8,000m+ without it — approximately 98% of Everest summiteers use supplemental oxygen
Reduces frostbite risk by improving peripheral circulation — peripheral vasoconstriction at extreme altitude without O₂ is a significant frostbite mechanism
The fatality rate for Everest without supplemental O₂ is significantly higher than with it — the exact differential is debated but the direction is not
The mainstream position: supplemental O₂ is appropriate and recommended for the vast majority of 8,000m climbers. The safety benefits are real and the ethical objection (that it artificially extends human capability into ranges our physiology isn’t adapted for) is itself not a safety argument.
A small number of physiologically exceptional climbers can function safely at 8,000m+ without supplemental O₂ — for these climbers, O₂ represents a technical aid that changes the nature of the ascent
The mountaineering tradition of the “fair means” ascent — using only the body’s natural capacity — has genuine philosophical weight for many serious alpinists
Supplemental oxygen dependence creates a specific failure mode: regulator failure, mask seal failure, or bottle depletion at extreme altitude produces a sudden transition to full altitude exposure without prior acclimatisation to that level — potentially more dangerous than a controlled non-O₂ ascent by a prepared climber
On “easier” 8,000m peaks (Cho Oyu, Broad Peak), experienced high-altitude climbers with prior 8,000m exposure can safely operate without supplemental O₂ — using each peak as progressively higher altitude exposure training
The minority position — appropriate only for climbers with documented exceptional altitude tolerance, prior 8,000m experience, and a clear understanding that they are operating in a category where errors have less margin for correction. Not recommended for first 8,000m objectives by anyone.
Expert Guide Series — Complete
All 12 guides done. The expert tier is yours.
From the expert readiness assessment through expedition planning, Seven Summits strategy, 8,000m preparation, technical gear, fixed lines and crevasse rescue, permits, operator selection, training periodisation, objective hazard management, and the physiology that underpins every decision at extreme altitude — you now have the complete expert mountaineering knowledge framework. The objectives that required this guide are genuinely within planning range. Go climb something serious.
